{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:12Z","timestamp":1792508232802,"version":"4.5.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82272182"],"award-info":[{"award-number":["No. 82272182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Acute myeloid leukemia (AML) exhibits a pronounced ability to develop drug resistance and undergo disease relapse. Recent research has noticed that resistance to treatments could substantially be attributed to drug-tolerant persister (DTP) cells, which are capable of surviving under therapeutic pressures. These are transient, reversibly dormant cells with the capability to act as a reservoir for disease relapse. DTP cells utilize diverse adaptive strategies to optimize the ecological niche, undergo metabolic reprogramming, and interact with microenvironment. The persister state of AML is established through transient cellular reprogramming, thus allowing cells to survive the initial phase of drug therapy and develop drug resistance. Our review explores the identification and phenotypic characteristics of AML DTP cells, as well as their clinical relevance. We summarize the mechanisms underlying the persistence of AML DTP cells and the molecular attributes that define the DTP state. We further address the current challenges and future prospects of DTP-targeting approaches. Understanding these features may provide critical insights into novel therapeutic strategies aimed at targeting AML DTP cells, especially in the new era of immunotherapy against AML.<\/jats:p>","DOI":"10.3389\/fmed.2025.1586552","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:56:08Z","timestamp":1747313768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Meng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11427-023-2423-1","article-title":"Cancer profiles in China and comparisons with the USA: A comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors.","volume":"67","author":"He","year":"2024","journal-title":"Sci China Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions.","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/cancers13092256","article-title":"Etiology of acute leukemia: A review.","volume":"13","author":"Tebbi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: A population-based study.","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia.","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: New drugs and new challenges.","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/1535-7163.MCT-19-0360","article-title":"Development of a novel multi-isoform ALDH inhibitor effective as an antimelanoma agent.","volume":"19","author":"Dinavahi","year":"2020","journal-title":"Mol Cancer Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105013","DOI":"10.1016\/j.isci.2022.105013","article-title":"Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.","volume":"25","author":"van Gils","year":"2022","journal-title":"iScience."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/CM9.0000000000002235","article-title":"Current status and prospects of hematopoietic stem cell transplantation in China.","volume":"135","author":"Wang","year":"2022","journal-title":"Chin Med J (Engl)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3324\/haematol.2024.286018","article-title":"Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.","volume":"110","author":"Morgenstern","year":"2024","journal-title":"Haematologica."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1002\/mco2.342","article-title":"Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells.","volume":"4","author":"Song","year":"2023","journal-title":"MedComm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaay1167","DOI":"10.1126\/scisignal.aay1167","article-title":"Slow growth causes bacterial persistence.","volume":"12","author":"Kaldalu","year":"2019","journal-title":"Sci Signal."},{"key":"B19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrmicro3076","article-title":"A problem of persistence: Still more questions than answers?","volume":"11","author":"Balaban","year":"2013","journal-title":"Nat Rev Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: The deadly survivors.","volume":"183","author":"Shen","year":"2020","journal-title":"Cell."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","article-title":"Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer.","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cancers13112666","article-title":"Emerging insights into targeted therapy-tolerant persister cells in cancer.","volume":"13","author":"Cabanos","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cancers13051118","article-title":"Fighting drug resistance through the targeting of drug-tolerant persister cells.","volume":"13","author":"De Conti","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-020-0120-3","article-title":"Switching off DNA repair-how colorectal cancer evades targeted therapies through adaptive mutability.","volume":"5","author":"Fahrer","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","article-title":"Drug resistance and combating drug resistance in cancer.","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"B27","doi-asserted-by":"publisher","first-page":"780192","DOI":"10.3389\/fmolb.2021.780192","article-title":"A transient metabolic state in melanoma persister cells mediated by chemotherapeutic treatments.","volume":"8","author":"Karki","year":"2022","journal-title":"Front Mol Biosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.lungcan.2024.107885","article-title":"Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.","volume":"194","author":"Izumi","year":"2024","journal-title":"Lung Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41416-021-01566-9","article-title":"Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours.","volume":"125","author":"Ishida","year":"2021","journal-title":"Br J Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.drup.2023.101007","article-title":"Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells.","volume":"71","author":"Szeb\u00e9nyi","year":"2023","journal-title":"Drug Resist Updat."},{"key":"B31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41419-024-06674-x","article-title":"ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.","volume":"15","author":"B\u00f6pple","year":"2024","journal-title":"Cell Death Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","article-title":"Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy.","volume":"3","author":"\u00c1lvarez-Varela","year":"2022","journal-title":"Nat Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1182\/blood-2023-178995","article-title":"AML Drug tolerant persister (DTP) cells survive chemotherapy by transiently altering cellular lipidomics to increase plasma membrane rigidity, but also increases sensitivity to immune cell killing.","volume":"142","author":"Morgenstern","year":"2023","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.","volume":"14","author":"Aitken","year":"2021","journal-title":"J Hematol Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1447001","DOI":"10.3389\/fonc.2024.1447001","article-title":"Immunophenotyping myelodysplastic neoplasms: The role of flow cytometry in the molecular classification era.","volume":"14","author":"Verigou","year":"2024","journal-title":"Front Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.","volume":"74","author":"Raha","year":"2014","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-Cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model.","volume":"18","author":"Moghal","year":"2023","journal-title":"J Thorac Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy.","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell."},{"key":"B40","doi-asserted-by":"publisher","first-page":"167693","DOI":"10.1016\/j.bbadis.2025.167693","article-title":"Single-cell RNA sequencing and machine learning provide candidate drugs against drug-tolerant persister cells in colorectal cancer.","volume":"1871","author":"Nojima","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e09462","DOI":"10.7554\/eLife.09462","article-title":"Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.","volume":"5","author":"Haven","year":"2016","journal-title":"Elife."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.stem.2023.09.013","article-title":"Hematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands.","volume":"30","author":"Kasbekar","year":"2023","journal-title":"Cell Stem Cell."},{"key":"B43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia.","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood-2014-12-570200","article-title":"Hematopoietic stem cells: Concepts, definitions, and the new reality.","volume":"125","author":"Eaves","year":"2015","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/ijc.26318","article-title":"Leukemia stem cells.","volume":"129","author":"Buss","year":"2011","journal-title":"Int J Cancer."},{"key":"B46","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: From biological questions to clinical opportunities.","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1542306","DOI":"10.3389\/fonc.2024.1542306","article-title":"Editorial: Acute leukemias: molecular characterization, leukemia-initiating cells, and influence of the microenvironment, volume II.","volume":"14","author":"Varisli","year":"2025","journal-title":"Front Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/bloodadvances.2020001742","article-title":"Delineation of target expression profiles in CD34+\/CD38- and CD34+\/CD38+ stem and progenitor cells in AML and CML.","volume":"4","author":"Herrmann","year":"2020","journal-title":"Blood Adv."},{"key":"B49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","article-title":"Principles and mechanisms of non-genetic resistance in cancer.","volume":"122","author":"Bell","year":"2020","journal-title":"Br J Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence.","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov."},{"key":"B51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","article-title":"An embryonic diapause-like adaptation with suppressed myc activity enables tumor treatment persistence.","volume":"39","author":"Dhimolea","year":"2021","journal-title":"Cancer Cell."},{"key":"B52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature20578","article-title":"Inhibition of mTOR induces a paused pluripotent state.","volume":"540","author":"Bulut-Karslioglu","year":"2016","journal-title":"Nature."},{"key":"B53","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells.","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1331802","DOI":"10.3389\/fonc.2023.1331802","article-title":"Simulating neuronal development: Exploring potential mechanisms for central nervous system metastasis in acute lymphoblastic leukemia.","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","article-title":"Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.","volume":"42","author":"Goddard","year":"2024","journal-title":"Cancer Cell."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1207642","DOI":"10.3389\/fcell.2023.1207642","article-title":"Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.","volume":"11","author":"Fu","year":"2023","journal-title":"Front Cell Dev Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","article-title":"Mechanisms driving the immunoregulatory function of cancer cells.","volume":"23","author":"van Weverwijk","year":"2023","journal-title":"Nat Rev Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e14903","DOI":"10.15252\/emmm.202114903","article-title":"Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy.","volume":"14","author":"Zhang","year":"2022","journal-title":"EMBO Mol Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1465334","DOI":"10.3389\/fonc.2024.1465334","article-title":"Efficacy and safety of hypomethylating agents in the treatment of AML\/MDS patients relapsed post allogenetic hematopoietic stem cell transplantation.","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1158\/1538-7445.AM2023-3864","article-title":"Targeting IL-6\/STAT3 signaling in EGFR-mutant drug tolerant persister cells.","volume":"83","author":"Patel","year":"2023","journal-title":"Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.drudis.2020.11.032","article-title":"Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance.","volume":"26","author":"Shih","year":"2021","journal-title":"Drug Discov Today."},{"key":"B62","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J Biol Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting.","volume":"289","author":"Guo","year":"2022","journal-title":"FEBS J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12032-025-02611-w","article-title":"Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: Advancing precision oncology.","volume":"42","author":"Radhakrishnan","year":"2025","journal-title":"Med Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/0008-5472.CAN-14-2789","article-title":"Targeting the eIF4F translation initiation complex: A critical nexus for cancer development.","volume":"75","author":"Pelletier","year":"2015","journal-title":"Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1038\/s41467-019-13360-6","article-title":"An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.","volume":"10","author":"Shen","year":"2019","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nchembio776","article-title":"Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.","volume":"2","author":"Bordeleau","year":"2006","journal-title":"Nat Chem Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"104483","DOI":"10.1016\/j.ebiom.2023.104483","article-title":"Redox signaling in drug-tolerant persister cells as an emerging therapeutic target.","volume":"89","author":"Zhang","year":"2023","journal-title":"EBioMedicine."},{"key":"B69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","article-title":"PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells.","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1532857","DOI":"10.3389\/fonc.2024.1532857","article-title":"Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.","volume":"14","author":"Tjahjono","year":"2025","journal-title":"Front Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism.","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"913669","DOI":"10.3389\/fonc.2022.913669","article-title":"Glutathione peroxidase 4 as a therapeutic target for anti-colorectal cancer drug-tolerant persister cells.","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1522239","DOI":"10.3389\/fonc.2025.1522239","article-title":"Prognostic value of serum lipids in newly diagnosed acute promyelocytic leukemia.","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"lnae040","DOI":"10.1093\/lifemedi\/lnae040","article-title":"Metabolic orchestration of drug-tolerant persister cells in cancer.","volume":"3","author":"Nie","year":"2024","journal-title":"Life Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer.","volume":"12","author":"Dong","year":"2021","journal-title":"Front Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13046-021-02145-9","article-title":"Therapeutic inhibition of GAS6-AS1\/YBX1\/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia.","volume":"40","author":"Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3892\/ol.2017.6497","article-title":"Cancer associated fibroblasts: An essential role in the tumor microenvironment.","volume":"14","author":"Tao","year":"2017","journal-title":"Oncol Lett."},{"key":"B78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11899-015-0253-6","article-title":"Role of microenvironment in resistance to therapy in AML.","volume":"10","author":"Tabe","year":"2015","journal-title":"Curr Hematol Malig Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/leu.2009.175","article-title":"Contribution of bone microenvironment to leukemogenesis and leukemia progression.","volume":"23","author":"Ayala","year":"2009","journal-title":"Leukemia."},{"key":"B80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","article-title":"The bone marrow microenvironment - Home of the leukemic blasts.","volume":"31","author":"Shafat","year":"2017","journal-title":"Blood Rev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1193978","DOI":"10.3389\/fonc.2023.1193978","article-title":"Cancer-associated fibroblasts in hematologic malignancies: Elucidating roles and spotlighting therapeutic targets.","volume":"13","author":"Ding","year":"2023","journal-title":"Front Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia propagating cells rebuild an evolving niche in response to therapy.","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood.2019001398","article-title":"Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.","volume":"134","author":"Burt","year":"2019","journal-title":"Blood."},{"key":"B84","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12185-017-2184-6","article-title":"Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.","volume":"105","author":"Camacho","year":"2017","journal-title":"Int J Hematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2015.03.002","article-title":"Shaping of the tumor microenvironment: Stromal cells and vessels.","volume":"34","author":"Blonska","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fimmu.2017.00909","article-title":"Anti-inflammatory mechanisms triggered by apoptotic cells during their clearance.","volume":"8","author":"Szondy","year":"2017","journal-title":"Front Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0959-437x(00)00193-3","article-title":"Activation of the HIF pathway in cancer.","volume":"11","author":"Maxwell","year":"2001","journal-title":"Curr Opin Genet Dev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/1078-0432.CCR-19-0253","article-title":"A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.","volume":"25","author":"Aloia","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41467-019-09634-8","article-title":"Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance.","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1022979","DOI":"10.3389\/fonc.2022.1022979","article-title":"Cancer-associated fibroblasts in acute leukemia.","volume":"12","author":"Gu","year":"2022","journal-title":"Front Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"992762","DOI":"10.3389\/fimmu.2022.992762","article-title":"Therapeutic strategies for gastric cancer targeting immune cells: Future directions.","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1394816","DOI":"10.3389\/fphar.2024.1394816","article-title":"Breaking the barrier: Nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint.","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity."},{"key":"B95","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: The possible implications for immunotherapy with CTLA-4 blocking antibody.","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumour Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/cancers13061203","article-title":"Immunosuppressive cell subsets and factors in myeloid leukemias.","volume":"13","author":"Swatler","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B97","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cellimm.2008.06.002","article-title":"Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression.","volume":"253","author":"Nasef","year":"2008","journal-title":"Cell Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3892\/ol.2012.614","article-title":"Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-\u03b2 in acute myeloid leukemia.","volume":"3","author":"Wu","year":"2012","journal-title":"Oncol Lett."},{"key":"B99","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","article-title":"Inflammation and immune escape in ovarian cancer: Pathways and therapeutic opportunities.","volume":"18","author":"Liu","year":"2025","journal-title":"J Inflamm Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment.","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B101","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2159-8290.CD-21-0560","article-title":"Systematic profiling of DNMT3A variants reveals protein instability mediated by the DCAF8 E3 ubiquitin ligase adaptor.","volume":"12","author":"Huang","year":"2022","journal-title":"Cancer Discov."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1084\/jem.20171056","article-title":"FLT3 dancing on the stem cell.","volume":"214","author":"Levis","year":"2017","journal-title":"J Exp Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell."},{"key":"B107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12929-018-0440-6","article-title":"Emerging roles of epithelial-mesenchymal transition in hematological malignancies.","volume":"25","author":"Chen","year":"2018","journal-title":"J Biomed Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/JTO.0b013e318216ee52","article-title":"Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.","volume":"6","author":"Suda","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.","volume":"91","author":"M\u00f6hle","year":"1998","journal-title":"Blood."},{"key":"B111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell."},{"key":"B112","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2020.10.001","article-title":"Extinguishing the embers: Targeting AML metabolism.","volume":"27","author":"Culp-Hill","year":"2021","journal-title":"Trends Mol Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jcp.22764","article-title":"Regulation of reactive oxygen species in stem cells and cancer stem cells.","volume":"227","author":"Kobayashi","year":"2012","journal-title":"J Cell Physiol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/cas.14316","article-title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.","volume":"111","author":"Kawakami","year":"2020","journal-title":"Cancer Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia.","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B116","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.stem.2010.07.007","article-title":"Oxygen in stem cell biology: A critical component of the stem cell niche.","volume":"7","author":"Mohyeldin","year":"2010","journal-title":"Cell Stem Cell."},{"key":"B117","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.stem.2007.07.017","article-title":"FoxO transcription factors and stem cell homeostasis: Insights from the hematopoietic system.","volume":"1","author":"Tothova","year":"2007","journal-title":"Cell Stem Cell."},{"key":"B118","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.stem.2018.05.021","article-title":"AMPK\/FIS1-mediated mitophagy is required for self-renewal of human AML stem cells.","volume":"23","author":"Pei","year":"2018","journal-title":"Cell Stem Cell."},{"key":"B119","doi-asserted-by":"publisher","first-page":"627","DOI":"10.18632\/aging.205409","article-title":"Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.","volume":"16","author":"Wu","year":"2024","journal-title":"Aging (Albany NY)."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","article-title":"RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer.","volume":"9","author":"Sui","year":"2018","journal-title":"Front Pharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: The cutting edges and future directions.","volume":"20","author":"Pu","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2024-204209","article-title":"Combinatorial therapy of CDK9 inhibitor with CD19 CAR-T to reciprocally overcome therapy resistance and enhance treatment efficacies against aggressive B-cell lymphomas.","volume":"144","author":"Yin","year":"2024","journal-title":"Blood."},{"key":"B123","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors.","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00277-023-05601-y","article-title":"Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0505-0","article-title":"Recent developments in immunotherapy of acute myeloid leukemia.","volume":"10","author":"Lichtenegger","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1080\/15384101.2015.1090063","article-title":"The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.","volume":"14","author":"Banelli","year":"2015","journal-title":"Cell Cycle."},{"key":"B128","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.18632\/oncotarget.23654","article-title":"Distinct histone modifications denote early stress-induced drug tolerance in cancer.","volume":"9","author":"Emran","year":"2018","journal-title":"Oncotarget."},{"key":"B129","first-page":"143","author":"Sarno","year":"2020","journal-title":"Histone Demethylase Inhibitors and Their Potential in Cancer Treatment. Histone Modifications in Therapy."},{"key":"B130","doi-asserted-by":"publisher","first-page":"149252","DOI":"10.1016\/j.brainres.2024.149252","article-title":"The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma.","volume":"1846","author":"Zhang","year":"2025","journal-title":"Brain Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00432-018-2631-7","article-title":"Therapeutic potential of GSK-J4, a histone demethylase KDM6B\/JMJD3 inhibitor, for acute myeloid leukemia.","volume":"144","author":"Li","year":"2018","journal-title":"J Cancer Res Clin Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","article-title":"Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.","volume":"39","author":"Marin-Bejar","year":"2021","journal-title":"Cancer Cell."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1021\/acs.jproteome.9b00773","article-title":"Proteomic analyses identify a novel role for EZH2 in the initiation of cancer cell drug tolerance.","volume":"19","author":"Pham","year":"2020","journal-title":"J Proteome Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","article-title":"A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer.","volume":"359","author":"June","year":"2018","journal-title":"Science."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/cancers14051241","article-title":"Emerging CAR T cell strategies for the treatment of AML.","volume":"14","author":"Vishwasrao","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1777064","DOI":"10.1080\/2162402X.2020.1777064","article-title":"Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors.","volume":"9","author":"Alcantara","year":"2020","journal-title":"Oncoimmunology."},{"key":"B139","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy.","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer.","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition.","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1374963","DOI":"10.3389\/fonc.2024.1374963","article-title":"Updates in novel immunotherapeutic strategies for relapsed\/refractory AML.","volume":"14","author":"Bawek","year":"2024","journal-title":"Front Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcdb.2023.11.003","article-title":"Persister cell plasticity in tumour drug resistance.","volume":"156","author":"McDonald","year":"2024","journal-title":"Semin Cell Dev Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/or.2023.8687","article-title":"Epigenetic regulation of mRNA mediates the phenotypic plasticity of cancer cells during metastasis and therapeutic resistance (Review).","volume":"51","author":"Zhang","year":"2023","journal-title":"Oncol Rep."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1080\/15548627.2023.2177398","article-title":"Mitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells.","volume":"19","author":"Li","year":"2023","journal-title":"Autophagy."},{"key":"B147","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/bs.acr.2022.12.006","article-title":"Epigenetic adaptations in drug-tolerant tumor cells.","volume":"158","author":"Mani","year":"2023","journal-title":"Adv Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/cancers16132490","article-title":"Transcriptomic analysis reveals early alterations associated with intrinsic resistance to targeted therapy in lung adenocarcinoma cell lines.","volume":"16","author":"Perez-Medina","year":"2024","journal-title":"Cancers (Basel)."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/cas.13266","article-title":"Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.","volume":"108","author":"Kunimasa","year":"2017","journal-title":"Cancer Sci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance.","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/microorganisms9112277","article-title":"Single-cell technologies to study phenotypic heterogeneity and bacterial persisters.","volume":"9","author":"Hare","year":"2021","journal-title":"Microorganisms."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity.","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell."},{"key":"B154","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.2021014670","article-title":"Single-cell genomics in AML: Extending the frontiers of AML research.","volume":"14","author":"Ediriwickrema","year":"2023","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1586552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:56:09Z","timestamp":1747313769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1586552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":154,"alternative-id":["10.3389\/fmed.2025.1586552"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1586552","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1586552"}}